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The pharmaceutical industry and disease mongering
The industry works to develop drugs, not
diseases
Editor—It is true that the pharmaceutical
industry, with others, is involved in sponsor›
ing the definition of diseases, as suggested by
Moynihan et al.1 Both the pharmaceutical
industry and regulatory authorities that
license new medicines need to develop
closely defined definitions so that the safety
and efficacy of new medicines can be
properly measured.
More medicalisation is in fact needed, as
indicated by Ebrahim and Bonaccorso and
Sturchio.2 3 The rise of guideline led care
around the Western world shows that far too
many serious diseases are underdiagnosed
and undertreated. Failure to put evidence
based medicine into practice is quite
legitimately addressed by the pharmaceuti›
cal industry. Examples include the underuse
of statins in the United Kingdom, the delay
in the uptake of thrombolysis during the
1980s, and reliance on old psychotropic
drugs when newer agents have a much more
favourable profile of side effects.
Of course, disease awareness campaigns
are likely to expand the market for drugs for
a given disease, but the market will expand
for competitors’ products as well as those of
the sponsoring company. However, the real
value of disease awareness campaigns is
exactly what it says: making consumers
aware that treatment may be available for
their condition. Not infrequently, major dis›
ease is detected as a result of a patient seek›
ing medical advice after contact with a
disease awareness campaign.
Moynihan et al imply that preventive
medicine is threatening the viability of pub›
licly funded healthcare systems. Yet clearly, it
is far better to prevent disease than to treat it
when it is established. The benefits of
stopping smoking, treating hypertension,
reducing raised blood lipid concentrations,
etc, are all well established but could not be
done without the help of the pharmaceuti›
cal industry.
In choosing the diseases that Moynihan
et al detail as sponsored by the pharmaceu›
tical industry, it is unfortunate that the Aus›
tralian experience has been highlighted. In
Europe patients cannot be targeted with
promotional material and such material for
health professionals in the United Kingdom
has to comply with the code of practice of
the Association of the British Pharmaceuti›
cal Industry. Moynihan et al imply that
osteoporosis has been effectively sponsored
by the pharmaceutical industry. However,
far too many people who fall and develop a
fracture are not considered for treatment of
osteoporosis.
In conclusion, the pharmaceutical
industry is not inventing disease but rather
working hard to develop new, innovative
drugs for the overall benefit of humankind.
Richard Tiner medical director
Association of the British Pharmaceutical Industry,
London SW1A 2DY
rtiner@abpi.org.uk
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Ebrahim S. The medicalisation of old age. BMJ
2002;324:861›3. (13 April.)
3 Bonaccorso SN, Sturchio JL Direct to consumer
advertising is medicalising normal human experience:
against. BMJ 2002;324:910›1. (13 April.)
Article was insulting to people with
osteoporosis
Editor—I was surprised that the BMJ
published the unbalanced and poorly
researched article of Moynihan in which
osteoporosis was dismissed as a “risk
masquerading as a disease” and compared
in severity to baldness.1
This article was insulting to all men
and women who have excruciating pain
and severe loss of quality of life from
osteoporosis.
The article wrongly stated that the risk
of fracture for most people is low: in fact 1 in
3 women and 1 in 12 men over 50 are
destined to have at least one fracture.
The article also implied that population
screening is advocated for osteoporosis: it is
not. Neither the National Osteoporosis
Society nor the International Osteoporosis
Foundation advocates screening all men and
women. However they do advocate that
those in high risk groups should seek their
doctor’s advice and be assessed. These same
groups are advocated in the Royal College
of Physicians’ report on osteoporosis and in
section six of the government’s national
service framework for older people.2 3
Moynihan et al also argued that we
should not ask pharmaceutical companies
to put money into campaigns to provide
information about the disease. Why not?
All profit making companies should be
expected to put money back into helping
patients, provided that they do not tell
patient organisations what to say. As a
national society, we follow strict guidelines in
our dealings with pharmaceutical compa›
nies, but we expect them to support some of
our work and the enlightened ones do. A
modest percentage of our income comes
from pharmaceutical companies, which is
useful, but we are not dependent on it.
A more appropriate target would be
health authorities that currently provide no
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service for patients with or at high risk of
osteoporosis, although good evidence shows
that it would be cost effective to treat to pre›
vent the high cost of further fractures.
The National Osteoporosis Society in
the United Kingdom and our sister societies
in other countries are certainly not
“attempting to persuade millions of healthy
women that they are sick,” but we do have a
duty to inform people about the seriousness
of osteoporosis. We must also provide infor›
mation about diet, exercise, and other
lifestyle measures that can be taken from the
cradle to extreme old age to help prevent
this devastating disease.
Linda Edwards director
National Osteoporosis Society, Bath BA2 0PJ
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Royal College of Physicians. Osteoporosis. London: RCP,
2001.
3 Department of Health. National service framework for older
people. London: DoH, 2001. (www.doh.gov.uk/nsf/
olderpeople.htm)
Drugs can be good for you too
Editor—Moynihan et al tell us that the mar›
keting departments of pharmaceutical com›
panies market pharmaceutical products.1
Shock horror. Well, tobacco companies mar›
ket cigarettes, McDonald’s markets junk
foods, and motor car manufacturers market
cars. The difference is that pharmaceutical
products can be good for your health.
To pick one of the examples given in the
paper: Moynihan et al would have us believe
that there is something evil about raising
awareness of social phobia. Social phobia is
a difficult disorder to define, as there is a
continuum from normal shyness to a
disabling psychiatric disorder, and it is not
therefore surprising that estimates of its
prevalence vary wildly.2 This should not
detract from the fact that many people
genuinely suffer from the disorder, and that
those people can be helped by treatment.3
Why is it wrong to help them?
Of course there is a conflict of interest
when pharmaceutical companies market
their products, and Moynihan et al are right
to point out that prescribers should be
aware of this when listening to the
marketing messages. We should not assume,
however, that advice about prescribing
originating from pharmaceutical companies
is wrong just because the company stands to
gain.
Moynihan et al recommend that infor›
mation provided by pharmaceutical compa›
nies should be replaced with information
from unbiased sources. This is a fine idea in
principle, but providing high quality infor›
mation is expensive. Who is going to pay for
it if not the pharmaceutical companies?
Adam Jacobs director
Dianthus Medical Limited, London SW19 3TZ
ajacobs@dianthus.co.uk
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Furmark T. Social phobia: overview of community surveys.
Acta Psychiatr Scand 2002;105:84›93.
3 Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J,
Beidel DC, et al. Consensus statement on social anxiety
disorder from the International Consensus Group on
Depression and Anxiety. J Clin Psychiatry 1998;59(suppl
17):54›60.
Authors were incorrect in their
comments about Osteoporosis Australia
Editor—Moynihan et al raise several
important issues in their article on disease
mongering, so it is a pity that they followed a
rule well known in journalism: “don’t let the
facts get in the way of a good story.”1
With respect to osteoporosis, they make
several incorrect assertions and are selective
in citing the literature. Osteoporosis Aus›
tralia is not a medical foundation but an
independent charity to promote the cause of
patients with osteoporosis. It has received
funding from industry but also from the fed›
eral and state governments. The risk test
developed by the International Osteoporo›
sis Foundation refers to women with an
early menopause before age 45, not “any
menopausal woman.” Also, it does not state
that a single risk factor is sufficient to justify
bone density testing, rather that a woman
should take the whole checklist to a doctor
for discussion about the need for further
testing.
The authors express concern that phar›
maceutical companies often fund meetings
“where the disease [is] being defined.”
Osteoporosis Australia and the National
Prescribing Service convened a fracture
summit in 2001 to develop an evidence
based approach to the management of
osteoporosis. This meeting, which included
representatives of the Pharmaceutical
Benefits Advisory Committee, specifically
excluded any funding by the pharmaceutical
industry. Its outcome concluded that there
was only weak evidence to support what the
authors suggest are “moderately effectively
non›pharmacological strategies, such as
weight bearing exercise.”2
The authors are selective in their report›
ing relating to bone density, which is widely
accepted as the best predictor of fracture
risk. The article by Wilkin quoted to suggest
that bone density is not an accurate
predictor of individual fracture risk was also
accompanied by a commentary that chal›
lenged this conclusion, but the author failed
to cite this counter view.3
It seems that the authors would have
people with osteoporosis be reassured that
they don’t have a real disease, just a risk
factor–low bone mass. Much of the rest that
the authors say is from “conversations with
industry insiders” and numerous personal
communications. This is not evidence but
hearsay. The article is written in tabloid style,
and perhaps a tabloid newspaper is where it
should have been published. Rational
debate is to be encouraged, but selective
reporting by authors with agendas is
inappropriate.
Philip Sambrook medical director
sambrook@med.usyd.edu.au
Judy Stenmark chief executive officer
Osteoporosis Australia, Forest Lodge NSW 2037,
GPO Box 121, Sydney, NSW 2001, Australia
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Preventing osteoporosis: outcomes of the Australian Frac›
ture Prevention Summit. Med J Aust 2002;176:S1›16.
3 Wilkin TJ. Changing perceptions in osteoporosis [with
commentary by R Eastell]. BMJ 1999;318:862›5.
It was ever thus
Editor—Moynihan et al’s article gave me an
overwhelming sense of dØjà vu.1 Long
before reading medicine as a mature
student, I did a degree in psychology and
spent several years in the late 1960s and
early ’70s working for a market research
company that specialised in qualitative or
“motivational” consumer research. Our task
was to use psychoanalytical techniques to
delve into the attitudes and motivations of
the consumer. Our purpose was to provide
companies’ marketing and advertising
departments with ammunition to exploit
the fears, weaknesses, and desires of con›
sumers so that they bought the companies’
products.
Three examples spring to mind: wom›
en’s worries about vaginal odour and
hygiene were exploited in order that vaginal
deodorants were sold; a new range of thera›
peutically useless pharmaceutical products
was developed for emerging Third World
markets, playing on the superstitions of the
uneducated, “native” mind; and “safe,” low
tar cigarettes were promoted to combat the
new government health warnings on ciga›
rette packets.
I am surprised that the medical world
took so long to catch on to the devious tech›
niques at which the pharmaceutical industry
excels. I have always been amazed by
doctors’ naivety in their uncritical accept›
ance of drug company sponsorship of medi›
cal education and their willingness to accept
the “evidence” of drug company representa›
tives about the wonderful properties of the
latest drug.
I have been a general practitioner for
11 years, but my memory of the methods
used in marketing and advertising is clear.
Jan Karmali general practitioner
The Surgery, Waddesdon, Aylesbury HP18 0LY
DrJanKarmali@gp›K82068.nhs.uk
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
DØjà vu all over again
Editor—Moynihan et al’s article on disease
mongering by the pharmaceutical industry1
reminded us of an old Bronx baseball
saying, originating with Yogi Berra: “It’s dØjà
vu all over again.” 3M has for years
sponsored the 3M/National Vaginitis
Association (www.vaginalinfections.com).
This produces a newsletter for health
professionals (the Vaginitis Report) and
materials for patients. Like the groups
described by Moynihan et al, the 3M/
National Vaginitis Association is ostensibly
an educational resource run by health
professionals.
Unfortunately, its activities include a
large element of disease mongering. Mild
Letters
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symptoms are offered as portents of serious
disease, and doctors are encouraged to be
aggressive in their attempts to diagnose and
treat vaginal infections, specifically bacterial
vaginosis. As luck would have it, 3M
produces a drug that treats bacterial vagino›
sis. More recently, the 3M/National Vaginitis
Association established a free telephone
number to distribute a free “educational
brochure” promoted by a television
personality.
The association provides a further
example of what Moynihan et al describe as
using statistics to “maximise the size of a
medical problem.” A survey sponsored by
the association found that “one›third of
women believe that vaginal odor is normal,
and approximately 24% believe that it’s nor›
mal to experience vaginal itching.’’2 This is
offered as evidence of women’s “lack of
knowledge” about vaginal health. The
association’s website encourages women to
contact a healthcare provider when they
experience such symptoms.
In fact, good evidence from the primary
literature says that both odour and itching
occur in women without vaginal com›
plaints.3 4 The idea that vaginal complaints
are due to infectious agents has been heavily
promoted by 3M through the association
and is implicit in the very naming of its web›
site, which refers to vaginal infections. Yet we
know that many women with vaginal
complaints do not have an identifiable infec›
tious pathogen.5
It is time for clinicians to rethink the
almost reflexive response, encouraged by
the pharmaceutical industry and its front
groups, of reaching for the prescription pad
when a patient presents with vaginal
complaints. As Yogi Berra also said: “You
can observe a lot just by watching.”
Matthew Anderson assistant professor
andersonma@aol.com
Alison Karasz assistant professor
Montefiore Medical Center, Bronx, NY 10458, USA
Peter Lurie deputy director
Public Citizen’s Health Research Group,
Washington, DC 20009, USA
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 3M/National Vaginitis Association. National survey reveals
most women still are unaware of bacterial vaginosis (BV), the
most common vaginal infection. St Paul, MN: 3M/NVA, 2002.
(21 February 2002.)
3 Doty RL, Huggins GR. Changes in the intensity and pleas›
antness of human vaginal odors during the menstrual
cycle. Science 1975;190:1316›8.
4 Priestley C, Jones B, Dhar J, Goodwin L. What is normal
vaginal flora? Genitourinary Med 1997;73:23›8.
5 Centers for Disease Control and Prevention. Guidelines
for treatment of sexually transmitted diseases. MMWR
1998;47(RR›1).
Will industry’s latest moves promote
public health or private profit?
Editor—The issues raised by Moynihan et
al are borne out by research conducted by
the Consumers’ Association.1 2 We found
many examples of pharmaceutical compa›
nies forming alliances with patient organisa›
tions in order to get their marketing
messages out to a wider public under the
guise of providing patients with much
needed information. There is now a lot of
pressure to allow drug companies to reach
the public direct.
This raises some interesting and impor›
tant questions. For example, why would
pharmaceutical companies continue to fund
patient organisations when they can com›
municate with patients direct? How will this
affect what the patient organisations can do
and the people who rely on their infor›
mation and support? Will it increase the use
of the internet for the purchase of drugs that
doctors are not willing to prescribe, and
what will the safeguards and regulation be to
protect consumers from poor medical
advice through this route? Perhaps the most
important question of all is why proposals
are currently before the European Parlia›
ment to reduce regulation of the pharma›
ceutical industry and to enable direct to
consumer advertising of prescription
medicines.
All the available evidence shows that this
will bring about far reaching and extremely
negative consequences for public health
throughout the European Community in
order to satisfy commercial interests.
Sheila McKechnie director
Consumers’ Association, London NW1 4DF
Louise.Ansari@Which.co.uk
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Consumers’ Association. Promotion of prescription drugs:
public health or private profit? London: CA, 2001. (Policy
report.)
Psychiatry should not accept so much
commercial sponsorship
Editor—Moynihan et al mention social
phobia as one example of the manipulation
of medical knowledge by the pharmaceuti›
cal industry,1 but, as Double says, this process
is endemic in psychiatry.2 Since the 1950s
drug treatments have dominated psychiatric
practice and set the agenda for most psychi›
atric research, even though it remains
difficult to show that long term outcomes are
any different from those 100 years ago.3
The influence of the pharmaceutical
industry is particularly pernicious in psy›
chiatry, where the possibilities for colonising
ever more aspects of life are potentially lim›
itless. In psychiatry different paradigms and
approaches to treatment are hotly con›
tested. The financial muscle of the pharma›
ceutical industry has helped to favour a
predominantly biological view of psychiatric
disorder. This has submerged alternative
therapeutic approaches, even though user
led research indicates that service users find
a wide variety of non›medical approaches
valuable in coping with emotional distress.4
It is time to uncouple the alliance
between psychiatry and the pharmaceutical
industry. Users of psychiatric services are
profoundly suspicious of this alliance and
last year organised a demonstration against
sponsorship of the Royal College of
Psychiatrists’ conference.5 Members of the
Critical Psychiatry Network supported this
demonstration.
In the interest of education and science,
the medical colleges must be seen to be
independent from the commercial interests
of the pharmaceutical industry; there has to
be absolute transparency concerning the
relation between the colleges and the indus›
try. In February this year we wrote to the
president of the Royal College of Psychia›
trists requesting information about the
extent of drug company sponsorship. We
await a reply.
The Critical Psychiatry Network argues
that the Royal College of Psychiatrists must
decline commercial sponsorship for all edu›
cational activities, including its annual
conference. These steps are necessary to dis›
tance the profession from the industry and
improve its credibility with service users and
the public. We shall be campaigning actively
to achieve this.
Joanna Moncrieff co›chairperson, Critical Psychiatry
Network
Department of Psychiatry and Behavioural
Sciences, London W1N 8AA
j.moncrieff@ucl.ac.uk
Phil Thomas co›chairperson, Critical Psychiatry
Network
Bradford University, Bradford BD7 1BL
1 Moynihan R, Heath I, Henry D. Selling sickness: the phar›
maceutical industry and disease mongering [with com›
mentary by P C Głtzsche]. BMJ 2002;324:886›91. (13
April.)
2 Double D. The limits of psychiatry. BMJ 2002;324:900›4.
(13 April.)
3 Healy D, Savage M, Michael P, Harris M, Hirst D, Carter M,
et al. Psychiatric bed utilization: 1896 and 1996 compared.
Psychol Med 2001;31:779›90.
4 Faulkner A. Strategies for living: a report of user led research
into people’s strategies for living with mental distress. London:
Mental Health Foundation, 2000.
5 Psychiatry agenda set by drug firms. Guardian 9 July 2001.
Authors’ reply
Editor—We welcome the comments and
criticisms of our paper, seeing them as part
of what we hope will be an ongoing and
growing debate about disease mongering.
Many of the experiences and views
described in the correspondence confirm or
expand our concerns about these issues.
We note the acknowledgement by Tiner
from the Association of the British Pharma›
ceutical Industry that “the pharmaceutical
industry, with others, is involved in sponsor›
ing the definition of diseases” and welcome
his wider reactions to the BMJ’s theme issue
on medicalisation. Similarly we are pleased
to receive feedback from the National
Osteoporosis Society but reject assertions
that our article was unbalanced or poorly
researched.
In response to Jacobs, we agree that
pharmaceutical treatments can offer great
help to those who genuinely suffer from dis›
orders, including social phobia. However,
as he rightly points out, we recommend a
preference for independently funded
information about both disorders and
treatments.
In response to Sambrook and Sten›
mark’s letter from Osteoporosis Australia,
we acknowledge a mistake in relation to the
way our article reported on the recommen›
dations for the one minute risk test for
osteoporosis. However, regarding the
sources of funding for Osteoporosis Aus›
Letters
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tralia, the organisation’s website (www.
osteoporosis.org.au) mentions four spon›
sors, Aventis (a pharmaceutical company
that markets the drug risedronate), the Aus›
tralian Dairy Corporation, Kraft Singles (a
popular brand of sliced processed cheese),
and Caltrate (a brand of calcium supple›
ment marketed by Wyeth Australia). In other
words, while Osteoporosis Australia may
indeed receive funding from governments,
its site lists commercial sponsors that have a
vested interest in some of the activities of
Osteoporosis Australia and also appears to
be promoting some of the sponsors’
products.
We agree that the evidence for the
efficacy of exercise is not as strong as for
some drug interventions, as Sambrook and
Stenmark assert. However, systematic
reviews of randomised trials have shown an
attenuation of the decline in bone mineral
density with exercise,1 2 and a systematic
review found that some forms of supervised
exercise reduce the incidence of falls.3
Observational studies have shown a protec›
tive association between regular exercise
and hip fracture.4 The website of Osteoporo›
sis Australia recommends exercise for the
“prevention of osteoporosis.”
Sambrook and Stenmark attempt to dis›
credit our article by describing evidence
based on “conversations with industry in›
siders” and “personal communications” as
“hearsay.” Several of the “personal commu›
nications” to which they refer were inter›
views with pharmaceutical company repre›
sentatives to check facts and include
company arguments and perspectives. The
“conversations with industry insiders” and
other confidential interview material were
referred to in our article because of their
direct relevance. As these authors may or
may not know, public relations experts active
in corporate funded disease awareness cam›
paigns are often liable to be far more candid
in confidential interviews than in public “on
the record” statements.
Sambrook and Stenmark claim that
bone densitometry “is widely accepted as the
best predictor of future fracture risk.” We are
not sure what this statement means, but the
performance of the test is poor. In a review
of bone mineral density measurement the
British Columbia Office of Health Technol›
ogy Assessment summarised published data
from five independent evaluations of the
predictive performance of bone density
measurements.5 Depending on the thresh›
old values used and the assumed lifetime
incidence of hip fracture, studies reported
predictive values for positive results in bone
mineral density tests ranging from 8% to
36%. This report also emphasised that
women of menopausal age are most
commonly referred for testing. The majority
of these women are at low risk of
osteoporotic fracture within the next few
years. If the test leads to unnecessary
treatment and anxiety (typical effects of dis›
ease mongering), it may do more harm than
good. We do not seek to downplay the real
suffering caused by osteoporotic fractures,
and welcome the increasing emphasis on
various forms of prevention and effective
treatments of those at high risk, particularly
elderly people.
Ray Moynihan journalist
Australian Financial Review, GPO Box 506, Sydney,
NSW 2201, Australia
Iona Heath general practitioner
Caversham Group Practice, 4 Peckwater Street,
London NW5 2UP
David Henry professor of clinical pharmacology
School of Medical Practice and Population Health,
Faculty of Health, University of Newcastle, NSW
2308, Australia
1 Wolff I, van Croonenborg JJ, Kemper HC, Kostense PJ.
Twisk JW. The effect of exercise training programs on bone
mass: a meta›analysis of published controlled trials in pre›
and postmenopausal women. Osteoporosis International
1999;9:1›12.
2 Wallace BA, Cumming RG. Systematic review of
randomized trials of the effect of exercise on bone mass in
pre› and postmenopausal women. Calcified Tissue Inter›
national 2000;67:10›18.
3 Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE,
Cumming RG, Rowe BH. Interventions for preventing
falls in elderly people (Cochrane Review). In: Cochrane
Library. Issue 2. Oxford: Update Software, 2002.
4 Kannus P. Preventing osteoporosis, falls, and fractures
among elderly people. BMJ 1999;318:205›6.
5 Green CJ, Bassett K, Foerster V, Kazanjian A. Bone mineral
testing: does the evidence support its selective use in well women?
Vancouver: BC Office of Health Technology Assessment,
University of British Columbia, 1997. (BCOHTA 97:2T.)
Available at: www.chspr.ubc.ca/bcohta/pdf/bmd.pdf
(accessed 19 May 2002).
Brain drain and health
professionals
Is state ownership of health
professionals’ intellect being proposed?
Editor—In their editorial on the migration
of medical professionals Pang et al suggest
that “Just as intellectual property rights need
to be discussed by developed and developing
countries together, so also should the preser›
vation of the intellectual property of a nation,
embodied in its health professionals, be
addressed by international organisations.”1
Does this mean that the state or some
international organisation has a financial
claim on a person’s intellect? It is one thing
to require public service in exchange for
education as long as both parties agree
beforehand. It is quite another to extort
service or money from people who have
paid for their own education; this type of
action would be justified only at a time of
national calamity, such as a world war.
Because we so value liberty, most Ameri›
cans would find this view utterly preposter›
ous. Hopefully many British people will as
well.
David I Stein medical director
Milwaukee Pain Treatment Services, Wauwatosa, WI
53226, USA
info@milwaukeepain.com
1 Pang T, Lansang MA, Haines A. Brain drain and health
professionals. BMJ 2002;324:499›500. (2 March.)
Brain drain disseminates skill and
advances science
Editor—I cannot understand why some
people have difficulty understanding the
freedom of movement of professionals.1
Professionals move from one region to
another and from one country to another all
the time. It happens everywhere.
This phenomenon is nothing new. The
people who leave their country have their
reasons for going. Einstein left Germany for
the United States in the 1930s for fear of
Nazi persecution. Osler emigrated from
Canada to John Hopkins University in the
United States and eventually ended up in
Oxford, England. In the United States we
have a variety of professionals from all over
the earth. This phenomenon enriches
cultures, disseminates skill and information,
and advances science and technology.
I see the phenomenon as equivalent to
the free flow of trade. People lament what
occurs, but many of my classmates in
medical school have already given up medi›
cine as a career and have become business›
men. A few are driving taxis to make ends
meet.
I opted to go out and see the world, but
that has enabled me to embrace medicine as
a career. Had I stayed, God knows what
would have become of me. People make
their own living. Even in countries such as
the United Kingdom a quarter of medical
graduates leave the medical profession out
of despair.
Unless society improves the living
conditions of healthcare professionals,
people will continue to leave their profes›
sions or simply find a better position.
Thein H Oo clinical fellow in haematology and
medical oncology
Tufts University School of Medicine, Boston, MA
02111, USA
theinoo@pol.net
THO is a medical migrant.
1 Pang T, Lansang MA, Haines A. Brain drain and health
professionals. BMJ 2002;324:499›500. (2 March.)
Scientists can promote research relevant
to their countries after emigrating
Editor—Pang et al’s editorial describes how,
as a result of the brain drain, countries are
left with a reduced workforce to carry out
crucial activities.1 We should see where these
specialists go.
The brain drain has both positive and
negative aspects. Many specialists who
emigrate from low income and middle
income countries are attracted by inter›
national organisations helping to define
world health and development priorities.
The World Health Organization, for exam›
ple, attracts the best health specialists to ful›
fil its mandate to provide support and
guidance to ministries of health from 191
countries. And it should do: it would be hard
to imagine the top United Nations body that
guides health policies not having the best
specialists, or not having specialists from low
income and middle income countries with
experience of the countries concerned who
can argue their case.
Countries lose in one way but may gain
in another. In health research, for example,
scientists migrating from developing coun›
tries can promote research activity in prior›
ity areas relevant to their countries, thereby
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helping to improve the allocation of health
research funding to these areas. Their work
can be expected to have repercussions in
many low income and middle income coun›
tries, including their own. This is part of
their commitment to improving health con›
ditions in their countries.
Andres de Francisco senior public health specialist
Global Forum for Health Research, c/o World
Health Organization, 1211 Geneva 27, Switzerland
defranciscoa@who.int
1 Pang T, Lansang MA, Haines A. Brain drain and health
professionals. BMJ 2002;324:499›500. (2 March.)
Relocation is better term than brain drain
Editor—Freedom of movement is sup›
posed to be a human right, and the
movement of professionals from place to
place or country to country is not new.1
Given the world’s sociopolitical›economic
make up, why not make use of these profes›
sionals? This was the question that I put to a
professor at an American university. I was
interested in his views on what more could
be done to address the problem of the lack
of health professionals in Africa. He said
that governments there should address the
issue of the brain drain and why they
couldn’t keep the professionals.
I wondered why, given that the condi›
tions that created the brain drain still
continue, the countries are not finding
a way to use the vast repository of
knowledge that these professionals have.
Not only do they have knowledge about the
countries they come from, but many still
have strong ties with those countries. Their
knowledge of these countries and their
presence in the West put them in an advan›
tageous position. Perhaps we should view
this movement not as a brain drain but as a
relocation.
Professionals in developed countries
have better access to new techniques, drugs,
and the latest developments in health and
medicine, which may be relevant to a coun›
try in Africa. And, being from there, they
would be well placed to analyse, assess, or
advise on how these could best be used in an
African setting and make this knowledge
available to their counterparts at home. Yet
you rarely hear of any attempts to recruit
such people for their knowledge. There are
virtually no networks that tap this pool of
talent.
Prompted by recent developments in
antiretroviral therapy, the controversy over
prices, and how the drugs were unavailable
to Third World markets, I have been trying
to contact professionals from Africa who are
working in the United States and the United
Kingdom. These drugs have been available
for over a decade. Why is it only now that
African doctors are being trained in their
use? Clearly, the health professionals who
would be best placed to advise on such
drugs are those with access to them and with
experience in using them, and of course
they would be African health professionals
based abroad.
Rather than the movement of profes›
sionals being viewed in a negative light,
more effort needs to be made to find ways of
using their knowledge.
John Kiwanuka Ssemakula HIV/AIDS programme
manager
Africa›America Institute, New York, NY 10168,
USA
jssemakula@medilinks.org
1 Pang T, Lansang MA, Haines A. Brain drain and health
professionals. BMJ 2002;324:499›500. (2 March.)
Developed countries must say no to trade
in medical staff
Editor—The call for global solutions to the
problem of medical migration is welcome
indeed.1 Through its longstanding health
programmes in many developing countries
Save the Children is acutely aware of the
impact of medical migration and the factors
that cause it. One factor not touched on in
Pang et al’s editorial is the increasing
pressure on countries to see health services
as a potential source of export earnings in
the context of increasing liberalisation of
trade in services under the auspices of the
World Trade Organization.2
The World Bank is the most outspoken
proponent of this. In its Global Economic
Prospects 2002 it explores service sectors in
which developing countries could make bal›
ance of payments gains.3 It makes the
following recommendation: “Health ser›
vices are another area in which developing
countries could become major exporters,
either by attracting foreign patients to
domestic hospitals and doctors, or by
temporarily sending their health personnel
abroad.’’
There may be countries where there is a
genuine surplus of medical staff and where
an excellent health record justifies seeking
balance of payments gains through export›
ing health services. Cuba is the most obvious
example, and the government there has
established its own trading agency,
Servimed, to cater for foreign patients at
home and abroad. But most developing
countries are characterised by poor health
outcomes and chronic shortages of medical
staff. It is irresponsible to suggest that they
should become major exporters in the
health sector rather than marshalling all
available resources to address their own
health needs.
A binding international code for gov›
ernments and multilateral organisations
may well be the best way of dealing with
brain drain in the long term. In the immedi›
ate future, however, the World Bank should
desist from promoting medical migration as
an economic strategy for developing
countries.
John Hilary trade policy adviser
Save the Children, London SE5 8RD
j.hilary@scfuk.org.uk
1 Pang T, Lansang MA, Haines A. Brain drain and health
professionals. BMJ 2002;324:499›500. (2 March.)
2 Hilary J. The wrong model: GATS, trade liberalisation and chil›
dren’s right to health. London: Save the Children, 2001.
3 World Bank. Global economic prospects 2002. Washington,
DC: WB, 2001.
Cholestatic hepatitis in
association with celecoxib
Classification of drug associated liver
dysfunction is questionable
Editor—We appreciated the report by
O’Beirne and Cairns concerning a patient
with liver test dysfunction in the setting of
treatment with the COX 2 inhibitor
celecoxib.1 We are, however, concerned at
their use of “cholestatic hepatitis” as the
most appropriate description of the pattern
of liver test abnormality observed. The
patient they described had a maximal aspar›
tate transaminase concentration of 1650
IU/l (reference range 10›40 IU/l), a
maximal alkaline phosphatase concentra›
tion of 232 IU/l (25›115 IU/l), and peak
total serum bilirubin of 123 ìmol/l
(5›20 ìmol/l).
In broad terms, two categories of drug
associated liver injury are encountered com›
monly, namely cholestatic and hepatocellu›
lar.2 Cholestatic injury has been defined
further as occurring when the peak
transaminase concentration is less than
eight times the upper limit of normal, and
the corresponding ALP is greater than
threefold normal, whereas hepatocellular
injury has been defined as being present
when the peak transaminase concentration
is greater than eight times the upper limit of
normal and the concomitant alkaline phos›
phatase concentration is less than threefold
normal. A mixed pattern of injury, showing
features of both, may also be found.3
According to these criteria the patient of
O’Beirne and Cairns had evidence of
hepatocellular injury primarily, rather than a
mixed pattern as the term “cholestatic hepa›
titis” suggests. Liver biopsy might have
helped to emphasise this distinction.
The article by Maddrey et al referred to
in their report was misquoted4: where the
term alkaline phosphatase was used, it
should have read alanine aminotransferase.
In that study only 0.4% and 0.3% respec›
tively of 6376 patients treated with celecoxib
had maximal alanine aminotransferase and
aspartate transaminase concentrations
greater than or equal to three times the
upper limit of normal. None of these
transaminase elevations was greater than
eight times the upper limit of normal, in
contrast to that found in the patient of
O’Beirne and Cairns (about 41 times upper
normal limit).
Therefore, although we disagree with
the view that this patient had cholestatic
hepatitis on the basis of data quoted, the
case does represent the first reported
instance of severe hepatocellular liver
dysfunction in association with celecoxib
treatment.
Faiyaz Mohammed specialist registrar
Alastair D Smith consultant gastroenterologist
adsmith_uk@yahoo.com
Department of Medicine, Eastbourne District General
Hospital, Eastbourne BN21 2UD
Competing interests: None declared.
1 O’Beirne JP, Cairns SR. Cholestatic hepatitis in association
with celecoxib. BMJ 2001; 323: 23. (7 July.)
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3 Lake›Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions
associated with ketoconazole in the United Kingdom. BMJ
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4 Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The
hepatic safety and tolerability of the novel
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2000;7:153›8.
Authors’ reply
Editor—We thank Smith and Mohammed
for their interest in our drug point. They
correctly identify the unintentional error in
paragraph 6. We agree that according to the
classification system they quote our case
would qualify as a hepatocellular rather than
a cholestatic reaction. But this system is
outdated.
Despite the publication of a consensus
document on classification of drug induced
liver disorders in 1990,1 disagreement still
persists about the nomenclature of drug
induced liver injury. This issue was discussed
at a joint conference between the American
Association for the Study of the Liver and
the Food and Drug Administration in
February 2001.2
Cholestatic hepatitis cannot be diag›
nosed firmly without performing a liver
biopsy. It is, however, not our practice to per›
form a liver biopsy on patients with rapidly
normalising abnormalities after a liver func›
tion test. We used the term cholestatic hepa›
titis as we were impressed by the severe
symptoms of cholestasis displayed by the
patient in our report—namely, jaundice,
dark urine, pruritus, and biochemical
hepatitis.
Three reports can be found in the litera›
ture of similar reactions to COX 2 inhibitors,
two of these biopsy proven to be cholestatic
hepatitis.3–5 We therefore remain comfort›
able with our use of the term cholestatic
hepatitis to describe the liver test abnormali›
ties shown in our report.
James P O’Beirne specialist registrar
Institute of Liver Studies, Kings College Hospital,
London SE5 9RS
Stuart Cairns consultant gastroenterologist
Digestive Disease Centre, Royal Sussex County
Hospital, Brighton BN2 5BE
Competing interests: None declared.
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BMA president clarifies his
message
Editor—Linda Beecham’s summary of my
inaugural speech as president of the BMA
(13 July, p 66) is efficient and fair.1 It does,
however, contain one minor but important
misrepresentation.
I did not describe a third of NHS care as
“similar to medicine in the third world.” My
precise and carefully chosen words were:
“Looking at the lowest third of NHS
performance, we are, in terms of availability,
verging on third world medicine, in what is
one of the most affluent countries in the
world.” The key words were “availability” and
“verging.” I also said, ‘‘broadly, two thirds of
NHS medicine is very good, or reasonably
good,” and my major concern was for the
very many patients who cannot get access to
that care without lengthy and (to me) un›
acceptable delays.
The separate issue of whether a presi›
dent of the BMA should express such
personal concerns is, I accept, a valid matter
for debate.
Tony Grabham president
BMA, London WC1H 9JP
1 Beecham L. New BMA president compares a third of NHS
care to care in the developing world .BMJ 2002;325:66. (13
July.)
Post›traumatic psychological
distress may present in
rheumatology clinics
Editor—In their Lesson of the Week
Gabriel and Neal mentioned that somatisa›
tion of mental disharmony may obscure the
diagnosis.1 Their report concentrated on
post›traumatic stress disorder in military
personnel, but other groups may have
experienced horrific experiences causing
spinal pain that results in referral to
rheumatologists.
We have reviewed clinic letters of
patients seen between June 2001 and Febru›
ary 2002 in a rheumatology clinic specialis›
ing in spinal pain. Three new patients
referred with spinal pain had clear evidence
of post›traumatic psychological distress.2–4
Case 1—A 25 year old Iraqi student was
referred with a history of torture. He had
been beaten by the police all over his body,
including the spine, on several occasions. He
was afraid to go to sleep because of dreams
that someone would come for him and take
him away. He wakes up screaming, dreaming
of his torture.
Case 2—A 39 year old Afghanistani
woman who was referred told how the Tali›
ban had imprisoned her and her husband;
she described being beaten with cables
across the back and the feet. She was tearful
and described crying out for no apparent
reason, saying, “I can’t help it; I can’t control
it.” She then said, “I try not to sleep. If I sleep
I have bad dreams.”
Case 3—A 57 year old white woman had
walked to her flat three years previously and
been assaulted from behind when her hand›
bag was stolen. She was thrown down steps
outside her flat and had never entered it
since, staying with her son. She now never
leaves her home unaccompanied.
We find it concerning that the trauma
was noted for only one of the referrals; that
waiting times to be seen by the Medical
Foundation for the Care of Victims of
Torture now exceed one year; and that Har›
row psychological services are not resourced
to meet these needs. As the physical aspects
of care are unlikely to resolve until the
psychological issues are addressed, areas
where torture victims live need adequate
psychological services. Case 3 exemplifies
the issues raised by relatively minor physical
trauma resulting in emotional distress and
major behavioural change, as has been
noted after road traffic incidents.5
John McCarthy specialist registrar in rheumatology
Andrew Frank consultant physician in rehabilitation
medicine and rheumatology
jfmeck@talk21.com
1 Gabriel R, Neal LA. Post›traumatic stress disorder
following military combat or peace keeping. BMJ
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2 Frank AO. Understanding back injuries and back pain. In:
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3 Field LH. Post›traumatic stress disorder: a reappraisal. J R
Soc Med 1999;92:35›7.
4 Burnett A, Peel M. Asylum seekers and refugees in Britain:
the health of survivors of torture and organised violence.
BMJ 2001;322:606›9.
5 Frank AO. Psychiatric consequences of road traffic
accidents—hidden disabilities. BMJ 1993;307:1283.
Adults still account for many
deaths from chickenpox
Editor—It was good to learn from Brisson
et al’s letter that the trend of an increasing
number of deaths from chickenpox has
reversed in the three years since colleagues
and I completed our survey.1 2 However,
Brisson et al disagree with our claim that
deaths in adults are rising and state that this
is misleading.1
Our conclusion that adult deaths had
risen was based on statistics covering a
period of 31 years (1967›97). Among
certified deaths from chickenpox adults
accounted for 48% in 1967›77 (88 deaths in
11 years), 64% in 1978›85 (120 deaths in
eight years),3 and 81% in 1986›97 (269
deaths in 12 years).
The contention that our data are
misleading on the basis of three further
years of data compared with our span of
31 years clearly needs to be placed in
context. Moreover, there is a precedent for
periods of lower mortality, as discussed
below for the period 1989›91. The main
body of our paper stated that deaths from
chickenpox in adults have increased in
number and proportion. We inadvertently
used the present tense in the abstract and
cannot claim to see into the future.
We looked at deaths noted by the Office
for National Statistics for the 13 years
1985›97 (table). This table, which was not
published in our paper for reasons of space,
shows that, except in two years, the annual
number of deaths was fairly consistent. The
exceptions were 1989 and 1996, when the
case fatality rates based on consultation rates
from the Royal College of General Practi›
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tioners were also exceptional. We have no
explanation for this.
The total number of deaths in 1986›8,
1989›91, 1992›4, and 1995›7 were 26, 22, 27,
and 27 respectively. This does not show that,
as Brisson et al state, “The number of deaths
from chickenpox and case fatality rates were
significantly higher in 1995›7 [the period of
our study] than at any other period.” The
overall case fatality rates in the table do not
show this either.
The main messages of our paper are
that mortality from chickenpox is not negli›
gible; adults account for a high proportion
of deaths; and the number and proportion
of adult deaths increased substantially
between 1967 and 1997.
Norman Noah professor of public health
London School of Hygiene and Tropical Medicine,
London WCIE 7HT
norman.noah@lshtm.ac.uk
1 Brisson M, Edmunds WJ, Gay NJ, Miller E. Deaths from
chickenpox in adults are decreasing. BMJ 2002;324:609.
(9 March.)
2 Rawson H, Crampin A, Noah N. Deaths from chickenpox
in England and Wales 1995›7: analysis of routine mortality
data. BMJ 2001;323:1091›3.
3 Joseph CA, Noah N. Epidemiology of chickenpox in Eng›
land and Wales, 1967›85. BMJ 1988;296:673›6.
Evaluation of treatments is
threatened by EC directive
Editor—Singer and Müllner draw attention
to how the European Directive 2001/20/EC
might stop trials of treatments for patients
rendered suddenly mentally incapacitated
by, for example, cardiac arrest, head injury,
stroke, or status epilepticus.1 Many of these
patients are in no position to give the
consent that the directive demands for entry
into a clinical trial. Furthermore, they may
well not have a legally acceptable represen›
tative immediately available to give proxy
consent in situations where any delay in
starting treatment might be disastrous.
Sadly, in Scotland such trials may
already be impossible. The Adults with
Incapacity (Scotland) Act, 2000 requires
consent from the adult’s proxy or next of
kin; this is despite numerous attempts over
four years by medical researchers to explain
the consequences of this restriction to the
lawyers drafting the bill. The United States’s
solution to the problem is for a waiver of
consent in explicit and well defined circum›
stances and with appropriate safeguards.2
This position is also taken by the British
ethicist Doyal, who wrote, “To exclude them
from participation in research specific to
their conditions and treatments might
deprive both them and others of potential
benefit.’’3
Europeans should wake up to the threat
to the evaluation of treatments for millions
of future patients. The lawyers and politi›
cians must sort out just whose interest they
are protecting when framing European
legislation.
Charles Warlow professor of medical neurology
University of Edinburgh, Department of Clinical
Neurosciences, Western General Hospital,
Edinburgh EH4 2XU
cpw@skull.dcn.ed.ac.uk
Graham Teasdale professor of neurosurgery
University of Glasgow, Institute of Neurological
Sciences, Southern General Hospital NHS Trust,
Glasgow G51 4TF
Stuart Cobbe professor of cardiology
University of Glasgow, Royal Infirmary, Glasgow
G31 2ER
1 Singer EA, Müllner M. Implications of the EU directive on
clinical trials for emergency medicine. BMJ
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2 Wichman A, Sandler AL. Research involving critically ill
subjects in emergency circumstances: new regulations, new
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Rational, cost effective use of
investigations
Rising workload and costs in diagnostic
departments must be contained
Editor—Winkens and Dinant have high›
lighted some issues regarding the rising
workload in pathology.1 In 1985 the
workload in most diagnostic departments
in the United Kingdom was reported to
have been rising 10% a year whereas the
number of inpatients and outpatients
increased by less than 2% a year2; it is
roughly similar now. A review of laboratory
audits showed that the number of inappro›
priate tests requested by clinicians varies
from 5% to 95%.3
The common perception among physi›
cians is that these tests are cheap. Their unit
cost may be low, but they have a high cumu›
lative cost.3 The annual bill for operating
laboratory tests is greater than the annual
cost of operating computed tomographic
scanners.3
Several methods to modify clinicians’
use of diagnostic tests have been reported.
The most potent interventions are methods
that facilitate the preferred behaviour
through blocking inappropriate requests or
defaulting to the intended practice.4 In a
study in the United States several character›
istics were associated with a low level of
laboratory use: being a leader, being part of
a service group whose leader was a low user,
clinical experience, being board certified,
and being a graduate from “established”
medical schools in the north east of
America, Chicago, or California.5
The two most important reasons for the
rising workload and costs in laboratories is
the ease with which tests can be requested
and lack of ownership by clinicians, as the
problem is viewed largely as a laboratory
problem. Good leadership and medical
training are important. Thus consultants
should play a key part as leaders, and a
course on cost containment should be made
compulsory in the medical curriculum.
The concepts of “profile” and “routine”
should be abolished and investigations
tailored to individual needs. It must be made
mandatory for all junior doctors to get a
certificate of competence in laboratory use
from their consultants based on the infor›
mation produced by the laboratory.
The question we have to grapple with is
how we want to use our resources: whether
to have more investigations or to fund more
nurses, doctors, or such like to improve
patient care. I suspect that the response
would be similar to that of those people who
say that they would prefer higher taxes to
fund public services but vote otherwise in
the polling booth. The decision we make will
dictate the quality of NHS we have. Let’s
have more doctors and nurses.
Sudha Bulusu consultant chemical pathologist
Newham General Hospital, London E13 8RU
sudha.bulusu@newhamhealth.nhs.uk
1 Winkens R, Dinant G. Rational, cost effective use of investi›
gations in clinical practice. BMJ 2002;324:783›5. (30
March.)
2 Fowkes FGR. Containing the use of diagnostic tests. BMJ
1985;290:488›90.
3 Van Walraven C, Naylor CD. Do we know what
inappropriate laboratory utilization is? A systematic review
of laboratory clinical audits. JAMA 1998;280:550›8.
4 Solomon DH, Hashimoto H, Daltroy L, Liang MH.
Techniques to improve physicians’ use of diagnostic tests.
JAMA 1998;280:2020›7.
5 Freeborn DK, Baer D, Greenlick MR, Bailey JW.
Determinants of medical care utilization: physicians’ use of
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Numbers of certified deaths from chickenpox and estimated case fatality rates in England and Wales,
1985›97
Year
No of RCGP consultations
per 100 000
No of ONS certified
deaths
No of cases in
population* Case fatality rate per 100 000
1985 544 271 891 25 9.19
1986 556 278 890 25 8.96
1987 514 258 748 24 9.28
1988 621 313 729 30 9.56
1989 699 354 393 19 5.36
1990 552 280 858 24 8.55
1991 554 283 089 24 8.48
1992 653 334 839 27 8.06
1993 643 330 753 30 9.07
1994 623 321 593 23 7.15
1995 484 250 809 22 8.77
1996 597 310 500 39 12.56
1997 486 253 746 20 7.88
Average 579 276 295 26 9.22
RCGP=Royal College of General Practitioners. ONS=Office for National Statistics. *Based on RCGP consultation rates.
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Article gave unbalanced view of overuse
of diagnostic tests
Editor—Winkens and Dinant report
that diagnostic tests are overused by
medical practitioners, and they propose
various measures to curtail this problem.1
We believe, though, that their view is
unbalanced. Investigations should only be
done if they have potential therapeutic
implications, but patients are entitled to be
assessed adequately. Even experts’ recom›
mendations on appropriate diagnostic test›
ing may be outdated by the time they are
reported.
Patients with rheumatoid arthritis and
systemic lupus erythematosus have many
more cardiovascular events than other
patients.2 3 These events are a major deter›
minant of the long term morbidity and mor›
tality in these diseases. Abnormal cardiovas›
cular risk profiles in these diseases show
traditional risk factors such as dyslipidae›
mia2 3 and non›traditional ones such as a
raised acute phase response2 and raised
serum homocysteine concentrations.3
These risk factors are associated with
atherosclerosis in the two diseases.2 3 Recent
guidelines on the evaluation and manage›
ment of rheumatoid arthritis and lupus,
reported by the American College of Rheu›
matology, do not deal with the issue of
cardiovascular disease. We believe that not
evaluating cardiovascular risk—both clini›
cally and by laboratory testing—may no
longer be appropriate, and we start treat›
ment accordingly in rheumatoid arthritis
and lupus.
Similarly, gout is associated with athero›
sclerosis.4 Hyperuricaemia is a documented
manifestation of the metabolic syndrome or
insulin resistance syndrome, while the latter
predicts a threefold increase in the inci›
dence of cardiovascular events.4 Most
patients with gout have dyslipidaemia
among other treatable cardiovascular risk
factors.4 5 Snaith recently commented:
“There is much work to be done before writ›
ing a prescription for allopurinol.”5
Because of the costs involved in treating
cardiovascular disease, we think that the
assessment and treatment of cardiovascular
risk factors in rheumatoid arthritis, lupus,
and gout is cost effective, at least in the long
term.
Patrick H Dessein specialist physician
dessein@lancet.co.za
Anne E Stanwix head of department
Department of Rheumatology, Johannesburg
Hospital, University of the Witwatersrand, Parktown
2193, Johannesburg, South Africa
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Primary care organisations must take
charge of laboratory expenditure
Editor—Winkens and Dinant offer a
gloomy but realistic assessment of the many
attempts to change doctors’ behaviour
related to laboratory testing.1 The experi›
ence documented is similar in many respects
to that in New Zealand. In one area
here, however, comprehensive sustained
strategies achieved an appreciable reduction
in laboratory expenditure, and this has been
maintained over several years.
Pegasus Health in Christchurch is a pri›
mary care organisation similar in many
respects to the primary care groups and
trusts in England. It has a membership now
of 230 general practitioners with a global
budget of around NZ$80m (£25m;
US$39m; &38m), and it established a
comprehensive laboratory budget holding
programme in 1994. This was through a
contract with the then funding authority,
which enabled it to keep nearly all savings.
An evaluation after one year showed
that savings of 23% had been achieved and
that the pronounced variation between
groups with high and low costs per
consultation had been greatly reduced.2 3
The study conclusively showed that general
practitioners, within the incentive of a
defined budget and the ability to use savings
for improving patient services, were able to
make major savings with no evidence of any
reduction in the quality of care.
A subsequent study in Pegasus showed
that savings were being maintained but that
variation was still inappropriately high.4
There was some evidence that better quality
care was associated with lower expenditure.
Since then per capita expenditure on
laboratory services has been maintained at
between NZ$20 (£6.20) and NZ$25 (£7.75),
whereas the national cost weighted figure
per capita has risen to NZ$37 (£11.46).
Primary care organisations have gener›
ally sought to engage in budget holding of
laboratory services, but this has been
inhibited by a confused and conflicting con›
tracting process between funders and
primary care organisations. There have been
disagreements about setting budgets and
what levels of savings could be retained by
the primary care organisation. The experi›
ence is a prime example of the inability of
bureaucrats to collaborate effectively and
constructively with professional aspirations.
It is the main reason behind the failure to
extend the successful experience of Pegasus
to a wider constituency.
Much more constructive action will now
be needed as the new population funded
district health boards begin to grapple with
reducing their wide underfunding and over›
funding on laboratory and related services.
Having laboratory budgets held by primary
care organisations along the Pegasus model
seems to be the only answer.
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laurence.malcolm@cyberxpress.co.nz
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Bravo, brave BMJ, for the rapid
response section
Editor—As a subspecialist who formerly
rarely read a generalist journal, I am a total
convert to the BMJ, this treasury of free
thinking and repartee. The rapid response
section not only leads to a democratisation
of science and medicine (formerly we were
prevented from free participation by the
whims of editors), but unpublished ideas can
be circularised, and this can lead to research
and changes.1 Imagine Leonardo da Vinci in
today’s research climate without a research
grant. Many of his ideas would have been
ridiculed as preposterous.
I think a section of “New Ideas” needs
discussion, and even a place where that
negative result or study that has never seen
the light of day can be mentioned. I with
other colleagues spent several years on a
large prospective study of ploidy in lung
cancer, which refuted an inferior positive
study we had published in the Lancet. Not
surprisingly, this far more technically
advanced second study, with negative results,
was never accepted for publication. Every›
one had lost interest, and the erroneous
conclusions of the first paper stand in
perpetuity as a reminder of the stupidity of
medical publishing fashions. It remains in
my filing cabinet to this day.
As no counterpart to rapid responses
exists in unenlightened Australia (the land
of the endless long weekend), it is delightful
to share ideas from half a world away instan›
taneously and to be able to respond early to
articles while the Brits are asleep and before
the milkman arrives. Other journals should
get out of the telegraph›and›morse›code
era.
Roger Allen consultant thoracic and sleep physician
Private Practice Suite 299, Spring Hill, Brisbane,
Queensland 4000, Australia
rogerallen@ozemail.com.au
1 Delamothe T, Smith R. Twenty thousand conversations.
BMJ 2002;324:1171›2. (18 May.)
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